Helix BioPharma (TSE:HBP) Reaches New 1-Year Low – Should You Sell?

by · The Markets Daily

Shares of Helix BioPharma Corp. (TSE:HBP – Get Free Report) hit a new 52-week low during trading on Monday. The stock traded as low as C$0.85 and last traded at C$0.91, with a volume of 11058 shares traded. The stock had previously closed at C$0.98.

Helix BioPharma Stock Performance

The company has a fifty day moving average of C$1.58 and a two-hundred day moving average of C$1.62. The stock has a market capitalization of C$69.50 million, a P/E ratio of -22.75 and a beta of 0.72. The company has a debt-to-equity ratio of 2.44, a current ratio of 0.45 and a quick ratio of 1.03.

Helix BioPharma Company Profile

(Get Free Report)

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.

Further Reading